undamentalytics Newsletter
Sign in

Immuron Ltd income statement

In fiscal 2026, Immuron Ltd reported revenue of $5.2m, up 10.9% on the year before, operating income of −$2.6m (a -49.9% margin) and net income of −$2.5m. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Jun 20162017Jun 20172018Jun 20182019Jun 20192020Jun 20202021Jun 20212022Jun 20222023Jun 20232024Jun 20242025Jun 20252026Jun 2026
Revenue7301,0531,1291,4421,6901095551,2153,2144,7215,238
Cost of revenue220255325477462381753341,0271,6341,860
Gross profit5107991,1041,2301,228713808812,1883,0873,378
Research and development2,6413,4931,7507477911,0214771,7453,5242,3311,313
Selling and marketing685102131150159128178175222462436
General and administrative9631,0421,036————————
Operating income—−5,072−2,361−3,331−1,950−6,261−2,082−2,402−3,803−3,463−2,615
Interest expense————31465——
Income before tax−5,152−5,133−2,379−3,331−1,964−6,265−2,071−2,549−4,548−3,379−2,499
Net income−5,152−5,133−2,379−3,331−1,964−6,265−2,071−2,549−4,548−3,379−2,499
Diluted shares (average)——————6m6m6m6m7m
EBITDA—−5,068−2,357−3,327−1,920−6,229−2,052−2,370−3,773−3,430−2,586

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: IMRN vs IVAIMRN vs TSHAANL vs IMRN

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Immuron Ltd's SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Immuron Ltd.